{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:18:08Z","timestamp":1777670288740,"version":"3.51.4"},"reference-count":50,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T00:00:00Z","timestamp":1430092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T00:00:00Z","timestamp":1430092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:p>\n                    Oncolytic virotherapies based on adenovirus 5 (Ad5) hold promise as adjunctive cancer therapies; however, their efficacy when delivered systemically is hampered by poor target cell specificity and preexisting anti-Ad5 immunity. Ovarian cancer represents a promising target for virotherapy, since the virus can be delivered locally into the peritoneal cavity. Both epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor 1 (FGFR1) are overexpressed in the majority of human tumors, including ovarian cancer. To generate adenoviral vectors with improved tumor specificity, we generated a panel of Ad5 vectors with altered tropism for EGFR and FGFR, rather than the natural Ad5 receptor, hCAR. We have included mutations within AB loop of the viral fiber knob (KO1 mutation) to preclude interaction with hCAR, combined with insertions in the HI loop to incorporate peptides that bind either EGFR (peptide YHWYGYTPQNVI, GE11) or FGFR1 (peptides MQLPLAT, M*, and LSPPRYP, LS). Viruses were produced to high titers, and the integrity of the fiber protein was validated by Western blotting. The KO1 mutation efficiently ablated hCAR interactions, and significantly increased transduction was observed in hCAR\n                    <jats:sup>low<\/jats:sup>\n                    \/EGFR\n                    <jats:sup>high<\/jats:sup>\n                    cell lines using Ad5.GE11, while transduction levels using Ad5.M* or Ad5.LS were not increased. In the presence of physiological concentrations of human blood clotting factor X (hFX), significantly increased levels of transduction via the hFX-mediated pathway were observed in cell lines, but not in primary tumor cells derived from epithelial ovarian cancer (EOC) ascites samples. Ad5-mediated transduction of EOC cells was completely abolished by the presence of 2.5% serum from patients, while, surprisingly, incorporation of the GE11 peptide resulted in significant evasion of neutralization in the same samples. We thus speculate that incorporation of the YHWYGYTPQNVI dodecapeptide within the fiber knob domain may provide a novel means of circumventing preexisting Ad5 immunity that warrants further investigation.\n                  <\/jats:p>","DOI":"10.1089\/hum.2015.015","type":"journal-article","created":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T14:53:07Z","timestamp":1430232787000},"page":"320-329","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":42,"title":["Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies"],"prefix":"10.1177","volume":"26","author":[{"given":"Hanni","family":"Uusi-Kerttula","sequence":"first","affiliation":[{"name":"Cardiff University","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Legut","sequence":"additional","affiliation":[{"name":"Cardiff University","place":["United Kingdom"]},{"name":"Cardiff University","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Davies","sequence":"additional","affiliation":[{"name":"Cardiff University","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Jones","sequence":"additional","affiliation":[{"name":"Velindre Cancer Centre","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Hudson","sequence":"additional","affiliation":[{"name":"Velindre Cancer Centre","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Hanna","sequence":"additional","affiliation":[{"name":"Velindre Cancer Centre","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Stanton","sequence":"additional","affiliation":[{"name":"Cardiff University","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Chester","sequence":"additional","affiliation":[{"name":"Cardiff University","place":["United Kingdom"]},{"name":"Velindre Cancer Centre","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L.","family":"Parker","sequence":"additional","affiliation":[{"name":"Cardiff University","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,4,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0302-9"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71172-6"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.118"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3140"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-178459"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000277"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.261452898"},{"key":"e_1_3_3_9_2","first-page":"1057","article-title":"Coxsackie adenovirus receptor expression in carcinomas of the head and neck","volume":"32","author":"Wunder T","year":"2012","unstructured":"Wunder T, , Schumacher U, , Friedrich RE. Coxsackie adenovirus receptor expression in carcinomas of the head and neck. Anticancer Res, 2012; 32:1057\u20131062.","journal-title":"Anticancer Res"},{"key":"e_1_3_3_10_2","first-page":"325","article-title":"Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy","volume":"59","author":"Li Y","year":"1999","unstructured":"Li Y, , Pong RC, , Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res, 1999; 59:325\u2013330.","journal-title":"Cancer Res"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01748-X"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01878-08"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02696-06"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04721"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301389"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950018021"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-008532"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00663-07"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.01.016"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.241562"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.6.2804-2813.2000"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2001.0489"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-4058com"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700470"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1312"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2009.07448.x"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800575"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.0.CO;2-H"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku340"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bti770"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2008.197"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.2144\/000112993"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2002.0613"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-79-6-1461"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.3.1844-1852.1998"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/1749-8090-8-183"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301152"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc500545z"},{"key":"e_1_3_3_39_2","article-title":"EGFR-targeted poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation","author":"Ren H","year":"2014","unstructured":"Ren H, , Gao C, , Zhou L, et al. EGFR-targeted poly(ethylene glycol)-distearoylphosphatidylethanolamine micelle loaded with paclitaxel for laryngeal cancer: preparation, characterization and in vitro evaluation. Drug Deliv, 2014. [Epub ahead of print]","journal-title":"Drug Deliv"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24194"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp5001718"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.58"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/10611860701733328"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300214"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.11.013"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(02)46055-7"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-06-0069"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00216"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00912-1"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M105163200"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2044"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2015.015","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2015.015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2015.015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:56:19Z","timestamp":1777449379000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2015.015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,27]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1089\/hum.2015.015"],"URL":"https:\/\/doi.org\/10.1089\/hum.2015.015","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,27]]}}}